CDCA2 and colon adenocarcinoma: The observed resistance of COAD patients with elevated CDCA2, CDCA3, CDCA4, CDCA5, CDCA7, and CDCA8 expression levels to specific drugs, including PD-0325901, RDEA119, Trametinib, and Selumtinib, highlights the need for tailored therapeutic strategies targeting CDCA-driven pathways.